Anesthesia: Page 36

Oral bisphosphonates may up risk of esophageal cancer
By DrBicuspid.com staff writers
The U.S. Food and Drug Administration is continuing to review data from published studies to evaluate whether the use of oral bisphosphonates is associated with an increased risk of esophageal cancer.
July 20, 2011
2009 07 28 13 33 39 581 Fda Logo 70
New Heraeus desensitizer gel enhances patient comfort
By DrBicuspid.com staff writers
Heraeus Kulzer has introduced Gluma Desensitizer PowerGel, designed to promote patient comfort during prophies, especially for those who've experienced sensitivity due to receding gums.
July 19, 2011
CEL-SCI licenses head/neck cancer drug for Croatia, Serbia
By DrBicuspid.com staff writers
CEL-SCI has expanded its licensing agreement with Teva Pharmaceutical Industries for its cancer drug Multikine, CEL-SCI's investigational phase III drug for the treatment of head and neck cancer.
July 19, 2011
Do targeted cancer therapies have fewer oral side effects?
By Donna Domino
Targeted cancer therapies are generally thought to have fewer oral complications and milder side effects than conventional cancer chemotherapy. But a lit review in Oral Oncology found that most studies involving these therapies do not focus enough on the potential oral complications, especially when combined with other treatments.
June 28, 2011
2010 12 02 00 13 58 619 Cancer Cell 70
Syringe modification could reduce injection pain
By DrBicuspid.com staff writers
A syringe modification, which promises reduced pain for dental injections, has won a major innovation award for its creators. The syringe cartridge works by reducing the acidity of the injection by mixing in a neutralizing liquid just before the injection is delivered.
June 14, 2011
CEL-SCI extends clinical trials for head/neck cancer drug
By DrBicuspid.com staff writers
Pharmaceutical company CEL-SCI has begun phase III clinical trials for its immunotherapy drug Multikine in Hungary.
June 12, 2011
U.S. jury finds Novartis not liable for jaw disease
By Reuters Health
NEW YORK (Reuters) - A U.S. federal jury found that the bisphosphonate drug Zometa made by Novartis Pharmaceuticals was not to blame for the osteonecrosis of the jaw developed by a Rhode Island man who died of cancer in 2005.
May 26, 2011
2009 03 12 09 39 33 608 Gavel 70
Bayer launches new aspirin for faster pain relief
By DrBicuspid.com staff writers
Bayer HealthCare has introduced Bayer Advanced aspirin, which can relieve pain twice as fast as previous Bayer aspirin tablets, according to the company.
May 25, 2011
Herbs: The new antibiotics?
By DrBicuspid.com staff writers
Indian wild plants may play a role in fighting bacterial and fungal infections in the mouths of oral cancer patients, according to new research.
May 24, 2011
Behavioral therapy better than hypnosis for dental anxiety
By DrBicuspid.com staff writers
A recent study published in Psychotherapy and Psychosomatics examines alternatives to general anesthesia for patients who have dental anxiety. Cognitive behavioral treatment (CBT) was better than hypnosis among alternatives to general anesthesia for treating dental anxiety, the researchers found.
May 23, 2011
Cancer patients on bisphosphonates don't develop ONJ
By Rabia Mughal
Cancer patients on zoledronic acid and chemotherapy combined with the antiangiogenic agent bevacizumab who underwent a dental exam before starting treatment did not develop osteonecrosis of the jaw (ONJ), according to a new study in the Journal of the American Dental Association.
May 19, 2011
2011 03 21 11 32 57 244 Salivary Glands 70
Mother to sue VCU Dental Clinic for child's death
By DrBicuspid.com staff writers
A mother whose 6-year-old boy died while under sedation at Virginia Commonwealth University (VCU) Dental Faculty Practice in Richmond last year will file a lawsuit against the school this week, according to a story by WTVR CBS 6 News.
May 10, 2011
Previous Page
Page 36 of 56
Next Page